文献速递类风湿关节炎

Proximod(选择性鞘氨醇-1-磷酸受体1激动剂)在健康志愿者和类风湿关节炎患者中的评估:一项1期双盲随机安慰剂对照递增剂量试验

Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial.
PubMed 文献 · Lancet Rheumatol · 2024-10-22

该1期双盲随机安慰剂对照递增剂量试验在中国单中心开展,评估选择性S1PR1激动剂proximod在健康志愿者和类风湿关节炎患者中的安全性、药代动力学和初步疗效。Part 1中124名健康志愿者接受单次口服proximod(0.125–15 mg)或安慰剂,所有剂量耐受良好,无剂量相关不良反应或严重不良事件。Part 2中34名参与者(10名健康志愿者和24名RA患者)接受每日一次proximod 5 mg、10 mg或安慰剂共28天,RA患者各proximod组淋巴细胞计数下降,第28天左右达最低点,5 mg组较基线下降65.25%、10 mg组下降71.64%、安慰剂组下降20.57%。

要点

  • Part 1中proximod所有剂量(0.125–15 mg)单次口服耐受良好,未观察到剂量相关不良反应或严重不良事件。
  • Part 2中proximod相关不良事件以轻中度为主,8/10名健康志愿者和22/24名RA患者报告不良事件。
  • RA患者中proximod 5 mg组淋巴细胞较基线下降65.25%、10 mg组下降71.64%、安慰剂组下降20.57%。

核心结论

  • Proximod在28天治疗期内耐受性良好,展现出降低血淋巴细胞计数的潜力,作者认为其作为RA治疗潜在候选药物值得在后续临床研究中进一步探索。

研究设计与样本

  • 在中国单中心开展的两部分1期双盲随机安慰剂对照递增剂量试验。
  • Part 1纳入124名健康志愿者(平均年龄34.3岁,SD 6.9;女性62/124[50%],男性62/124[50%];汉族116/124[94%]),随机接受单次口服proximod 0.125 mg、0.25 mg、0.5 mg、1 mg、1.5 mg、2 mg、3 mg、5 mg、10 mg或15 mg(队列1–10)或安慰剂。
  • Part 2筛选113名参与者(80名健康志愿者和33名RA患者),排除79名后随机分配34名(10名健康志愿者和24名RA患者),健康志愿者接受每日一次proximod 5 mg或安慰剂,RA患者接受每日一次proximod 5 mg、10 mg或安慰剂,共28天。
  • 主要结局为健康志愿者72天和RA患者48天内的安全性、耐受性和药代动力学特征,在所有接受治疗的参与者中评估。

主要发现

  • Part 1中proximod所有剂量耐受良好,未观察到剂量相关不良反应或严重不良事件。
  • Part 2中8/10名健康志愿者(80%)和22/24名RA患者(92%)报告共74例不良事件,proximod相关不良事件以轻中度为主。
  • Part 2中proximod及其活性代谢物proximod-phosphate浓度在三个proximod组中逐渐升高,proximod-phosphate对S1PR1激动剂的EC50(6.1 ng/mL)在两个5 mg组于第14天达到,10 mg组于第7天达到。
  • 第28天proximod-phosphate平均Ctrough值:健康志愿者5 mg组为7.7 ng/mL,RA患者5 mg组为10.2 ng/mL,RA患者10 mg组为15.3 ng/mL。
  • RA患者中所有proximod组治疗后淋巴细胞计数下降,约第28天达最低点,较基线下降百分比:5 mg组65.25%,10 mg组71.64%,安慰剂组20.57%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proximod is a selective agonist of sphingosine-1-phosphate receptor-1 (S1PR1). It acts by redirecting lymphocytes from the circulation to secondary lymph nodes, and is under development as an immunomodulator for rheumatoid arthritis. We aimed to evaluate the safety, pharmacokinetics, and preliminary efficacy of proximod in healthy volunteers and patients with rheumatoid arthritis. METHODS: We did a two part, phase 1, double-blind, randomised, placebo-controlled, ascending dose trial at a single centre in China. Eligible participants were adults aged 18-50 years with a BMI of 18-28 kg/m2 for healthy volunteers and aged 18-70 years with a BMI of 18-30 kg/m2 for patients with rheumatoid arthritis. In part 1, healthy volunteers were randomly assigned within ten cohorts to receive a single oral dose of proximod (0·125 mg, 0·25 mg, 0·5 mg, 1 mg, 1·5 mg, 2 mg, 3 mg, 5 mg, 10 mg, or 15 mg in cohorts 1-10) or placebo. In part 2, healthy volunteers were randomly assigned to receive once-daily doses of proximod 5 mg or placebo, and patients with rheumatoid arthritis were randomly assigned to receive once-daily doses of proximod 5 mg, proximod 10 mg, or placebo, for 28 days. Patients and investigators were masked to treatment assignment. The primary outcomes were safety, tolerability, and pharmacokinetic profile of proximod for 72 days in healthy volunteers and for 48 days in patients with rhematoid arthritis, assessed in all treated participants. This trial is registered with ClinicalTrials.gov (NCT06361199, NCT06361186), and is complete. FINDINGS: Between Nov 1, 2017, and June 22, 2021, 124 healthy volunteers were randomly assigned in part 1 of the study and 124 were included in the analyses (mean age 34·3 years [SD 6·9], 62 [50%] of 124 participants were women and 62 [50%] were men, and 116 [94%] were Han Chinese ethnicity). Between Feb 16, 2022, and Oct 8, 2023, 113 participants were screened for inclusion in part 2 (80 healthy volunteers and 33 patients with rheumatoid arthritis). 79 participants were excluded and 34 were randomly assigned (10 healthy participants and 24 patients with rheumatoid arthritis), 34 of whom were included in the analyses. Ten (100%) of ten healthy participants were Han Chinese ethnicity, with a mean age of 39·9 years (SD 7·3). Five (50%) of ten healthy volunteers were women and five (50%) were men). 22 (92%) of 24 participants with rheumatoid arthritis were Han Chinese ethnicity, with a mean age of 52·7 years (SD 6·8). 22 (92%) of 24 patients with rheumatoid arthritis were women and two (8%) were men. In part 1, all doses of proximod were well tolerated, with no dose-related adverse reactions or serious adverse events observed. In part 2, 74 adverse reactions were reported in eight (80%) of ten healthy volunteers and 22 (92%) of 24 patients with rheumatoid arthritis. Adverse events associated with proximod were predominantly mild or moderate. In part 2, the concentration of proximod and its active metabolite, proximod-phosphate, gradually increased in all three groups receiving proximod and the EC50 of the S1PR1 agonist for proximod-phosphate (6·1 ng/mL) was reached on day 14 for both 5 mg groups, and on day 7 for the 10 mg group. The mean Ctrough values for proximod-phosphate on day 28 were 7·7 ng/mL and 10·2 ng/mL for 5 mg in healthy volunteers and patients with rheumatoid arthritis, respectively, and 15·3 ng/mL for 10 mg in patients with rheumatoid arthritis. In patients with rheumatoid arthritis, lymphocyte count decreased after treatment in all proximod groups reaching nadir at approximately day 28, with a corresponding percentage decline from baseline of 65·25% in the 5 mg group, 71·64% in the 10 mg group, and 20·57% in the placebo group. INTERPRETATION: Proximod exhibited good tolerability over the 28-day treatment period, demonstrating its potential in reducing blood lymphocyte count. These results highlight the promise of the S1PR1 agonist proximod as a potential candidate for rheumatoid arthritis treatment, warranting further investigation in subsequent clinical studies. FUNDING: Beijing Union Pharmaceutical Factory and Jian Kuan (Suzhou) Biotechnology.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Zhang H, Li Q, Li C, et al. Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial. Lancet Rheumatol. 2024. PMID: 39454617. doi:10.1016/S2665-9913(24)00199-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。